Dr. Scott M. Batchelor, M.D.
Pediatrics (Pediatrics Physician)
49 Jesse Hill Jr Dr Se, Emory Pediatrics Residency Training Program
Atlanta, GA 30303
At a glance
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
GA license 001342
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $75.75 in total to this clinician.
| Supernus Pharmaceuticals, Inc. | $30.31 |
|---|---|
| Sanofi Pasteur Inc. | $28.18 |
| Merck Sharp & Dohme LLC | $17.26 |
| Food and Beverage | $75.75 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $209,026 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Ultragenyx Pharmaceutical Inc. · Terminated · NCT06617429 - Long-term Extension of GTX-102 in Angelman Syndrome
Ultragenyx Pharmaceutical Inc. · Terminated · NCT06415344 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - Long term follow up study of patients with spinal muscular atrophy receiving risdiplam treatment
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.